GAMEPLAN: Gastrointestinal And Metabolic Effects From a Prebiotic, Lifting, and Aerobic iNtervention

Sponsor
University of Illinois at Urbana-Champaign (Other)
Overall Status
Recruiting
CT.gov ID
NCT05207488
Collaborator
(none)
48
1
2
11.6
4.1

Study Details

Study Description

Brief Summary

This study aims to determine the independent and combined effects of prebiotic fiber supplementation and exercise on the gut microbiome and human health.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Fructooligosaccharides (FOS)
  • Behavioral: Exercise
  • Dietary Supplement: Placebo
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
48 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The study is a randomized, controlled trial with a 6-week intervention period with two groups: 1) Exercise + Prebiotic and 2) Exercise + Placebo.The study is a randomized, controlled trial with a 6-week intervention period with two groups: 1) Exercise + Prebiotic and 2) Exercise + Placebo.
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
The study is a double-blind, placebo-controlled study.
Primary Purpose:
Prevention
Official Title:
Gastrointestinal And Metabolic Effects From a Prebiotic, Lifting, and Aerobic iNtervention (GAMEPLAN)
Actual Study Start Date :
Oct 1, 2021
Anticipated Primary Completion Date :
Sep 20, 2022
Anticipated Study Completion Date :
Sep 20, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Exercise + Prebiotic

The Exercise + Prebiotic intervention group will consume 10 g/d of fructo-oligosaccharides (FOS). Additionally, they will perform 6 wk. of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk).

Dietary Supplement: Fructooligosaccharides (FOS)
FOS (NUTRAFLORA® P-95, Ingredion) supplements (10g/day) will be consumed daily mixed with water.

Behavioral: Exercise
During the intervention period, all participants will perform 6 weeks of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk.).

Placebo Comparator: Exercise + Placebo

The Exercise + Placebo group will consume 10 g/d of a placebo (maltodextrin) powder every day. Additionally, they will perform 6 wk. of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk).

Behavioral: Exercise
During the intervention period, all participants will perform 6 weeks of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk.).

Dietary Supplement: Placebo
Maltodextrin (Globe 18DE Maltodextrin, Ingredion) supplements (10g/day) will be consumed daily mixed with water.
Other Names:
  • Maltodextrin
  • Outcome Measures

    Primary Outcome Measures

    1. Changes in gastrointestinal microbiota composition [Baseline & 6-week mark]

      Determine the impact of daily consumption of prebiotic combined with regular exercise on the gastrointestinal microbiota compared to control by sequencing the V4 region of the 16S rRNA gene in fecal samples.

    2. Changes in gastrointestinal microbial-derived metabolite concentrations [Baseline & 6-week mark]

      Determine the impact of daily consumption of prebiotic combined with regular exercise on the concentration of short-chain fatty acids compared to control.

    Secondary Outcome Measures

    1. Changes in fasting glucose [Baseline & 6-week mark]

      Determine the impact of daily consumption of prebiotic combined with regular exercise on fasting glucose compared to control.

    2. Changes in fasting insulin [Baseline & 6-week mark]

      Determine the impact of daily consumption of prebiotic combined with regular exercise on fasting insulin compared to control.

    3. Changes in body composition [Baseline & 6-week mark]

      Determine the impact of daily consumption of prebiotic combined with regular exercise on body composition compared to control. This includes percentage of fat mass and lean mass.

    4. Changes in body fat distribution [Baseline & 6-week mark]

      Determine the impact of daily consumption of prebiotic combined with regular exercise on body fat distribution compared to control. This includes the weight of visceral fat and liver fat in kilograms.

    5. Changes in cognition [Baseline & 6-week mark]

      Determine the impact of daily consumption of prebiotic combined with regular exercise on relational memory, hippocampal function, interference control, and selective attention compared to control. Outcomes will be assessed with computer tasks and participants will be equipped with an electrode cap.

    Other Outcome Measures

    1. Changes in lipid profiles [Baseline & 6-week mark]

      Determine the impact of daily consumption of prebiotic combined with regular exercise on fasting lipid profiles including cholesterol and triglycerides compared to control.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 45 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • BMI 18.5-45 kg/m2

    • Without physician diagnosed gastrointestinal or metabolic diseases

    • Sedentary (< 30 minutes of moderate or high intensity exercise per week and < 10 aggregate Godin-Shepard Leisure Time Physical Activity Questionnaire (GSLTQ; GodinLeisure) score)

    Exclusion Criteria:
    • Fasting blood glucose >126 mg/dL

    • Blood pressure >160/100 mm Hg

    • Physician diagnosed metabolic or gastrointestinal diseases or constipation

    • Heart conditions that may pose risk during exercise

    • Taking oral hypoglycemic agents or insulin

    • Pregnant, breastfeeding or postmenopausal

    • Smoke or consume > 2 alcoholic beverages/day, abuse drugs

    • Have had > 5% weight change in the past month or > 10% change in the past year

    • Have had any form of bariatric surgery or gallbladder removal

    • Have taken antibiotics during the previous 3 months

    • Unable to consume the experimental fiber

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Illinois at Urbana-Champaign Urbana Illinois United States 61801

    Sponsors and Collaborators

    • University of Illinois at Urbana-Champaign

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Illinois at Urbana-Champaign
    ClinicalTrials.gov Identifier:
    NCT05207488
    Other Study ID Numbers:
    • 21730
    First Posted:
    Jan 26, 2022
    Last Update Posted:
    Jan 26, 2022
    Last Verified:
    Jan 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University of Illinois at Urbana-Champaign
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 26, 2022